Literature DB >> 10598205

Expression of matrix metalloproteinase gelatinase A messenger ribonucleic acid in parathyroid carcinomas.

F Farnebo1, A Svensson, N W Thompson, M Bäckdahl, L Grimelius, C Larsson, L O Farnebo, K Sandelin.   

Abstract

BACKGROUND: The incidence of parathyroid cancer in patients with hyperparathyroidism is less than 1%. However, these few cases cause diagnostic problems in the absence of clear-cut invasion of adjacent organs or metastasis. New markers are needed to increase diagnostic accuracy.
METHODS: Thirty-one parathyroid tumors from patients with primary hyperparathyroidism were collected worldwide. Eighteen tumors were classified as unequivocal cancers, whereas 13 tumors were considered equivocal because of a lack of infiltrative growth or evidence of recurrence. Paraffin sections were hybridized with a 35S-labeled riboprobe complementary to gelatinase A mRNA, dipped in photographic emulsion, developed, counterstained, and then evaluated by light- and dark-field microscopy.
RESULTS: Fourteen of the 18 unequivocal parathyroid cancers expressed gelatinase A, as compared with the equivocal tumors, of which only 4 of 13 showed expression. The strongest hybridization signal was seen in stromal cells at the tumor border, most likely fibroblasts and macrophages. No expression was detected in tumor cells.
CONCLUSIONS: Invasive growth of many tumors is facilitated by proteolytic enzymes, such as gelatinase A. The presence of gelatinase A mRNA in parathyroid tumors strengthens the suspicion of malignancy but cannot be used as a definitive marker of malignancy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10598205     DOI: 10.1067/msy.2099.101420

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  3 in total

1.  Risk factors of thyroid cancer in Babol, Northern Iran.

Authors:  Zoleika Moazezi; Mahmoud Mahmoudi; Yousef Yahyahpour; Alireza Alaleh
Journal:  Caspian J Intern Med       Date:  2011

2.  Proposal for the histological classification of parathyroid carcinoma.

Authors:  Kaori Kameyama; Hiroshi Takami
Journal:  Endocr Pathol       Date:  2005       Impact factor: 3.943

3.  Parathyroid carcinomas: can clinical outcomes for parathyroid carcinomas be determined by histologic evaluation alone?

Authors:  Kaori Kameyama; Ronald A DeLellis; Ricardo V Lloyd; Kennichi Kakudo; Hiroshi E Takami
Journal:  Endocr Pathol       Date:  2002       Impact factor: 3.943

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.